recurrent ovarian cancer

https://publicatt.unicatt.it/handle/10807/148821 BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study recurrent ovarian cancer https://adisinsight.springer.com/trials/700318612?error=cookies_not_supported&code=baa6effc-c685-45cf-b20a-202b2da93520 A study evaluating rates of thrombocytopenia among recurrent ovarian cancer patients who initiated... The aim of this study is to assess the rates of thrombocytopenia among recurrent ovarian cancer patients who initiated niraparib 200 mg/d in a real-world US recurrent ovarian cancer https://ecancer.org/en/video/8318-safety-and-tolerability-of-avb500-in-platinum-resistant-recurrent-ovarian-cancer Safety and tolerability of AVB500 in platinum-resistant recurrent ovarian cancer - ecancer Dr Gail McIntyre speaks to ecancer at ESMO 2019 in Barcelona about a phase Ib study using AVB500 in combination with paclitaxel or pegylated liposomal doxoru recurrent ovarian cancer https://www.researchandmarkets.com/report/advanced-recurrent-ovarian-cancer-drug Advanced Recurrent Ovarian Cancer Market Size & Competitors Advanced Recurrent Ovarian Cancer - Market Insight, Epidemiology and Market Forecast - 2034 recurrent ovarian cancer market size advanced competitors https://pubmed.ncbi.nlm.nih.gov/24637997/ Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA... Adding bevacizumab to chemotherapy statistically significantly improved PFS and ORR; the OS trend was not significant. No new safety signals were observed. recurrent ovarian cancer https://www.hematologyandoncology.net/archives/october-2020/parp-inhibition-in-recurrent-ovarian-cancer/ PARP Inhibition in Recurrent Ovarian Cancer - Hematology & Oncology recurrent ovarian cancer parp inhibition hematology oncology https://ecancer.org/en/video/6276-ariel3-rucaparib-as-maintenance-therapy-in-recurrent-ovarian-cancer-patients ARIEL3: Rucaparib as maintenance therapy in recurrent ovarian cancer patients - ecancer Prof Ledermann speaks with ecancer at the ESMO 2017 Congress about the phase III ARIEL3 study of rucaparib vs placebo following response to platinu recurrent ovarian cancer maintenance therapy rucaparib https://publicatt.unicatt.it/handle/10807/148821 BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study recurrent ovarian cancer https://adisinsight.springer.com/trials/700318612?error=cookies_not_supported&code=baa6effc-c685-45cf-b20a-202b2da93520 A study evaluating rates of thrombocytopenia among recurrent ovarian cancer patients who initiated... The aim of this study is to assess the rates of thrombocytopenia among recurrent ovarian cancer patients who initiated niraparib 200 mg/d in a real-world US recurrent ovarian cancer https://pure.fujita-hu.ac.jp/en/publications/effects-of-third-line-chemotherapy-for-women-with-recurrent-ovari/ Effects of third-line chemotherapy for women with recurrent ovarian cancer who received... https://www.bmsstudyconnect.com/it/en/clinical-trials/NCT01611558.html Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer | BMS Study... To assess the incidence of drug-related adverse events of Grade 3 or higher and the overall response associated with ipilimumab treatment

Robuta